Cancer therapy: Altering mitochondrial properties.
Department of Morphology, Surgery and Experimental Medicine and the Section of Pathology, Oncology and Experimental Biology at the Interdisciplinary Center for the Study of Inflammation (ICSI), Laboratory for Technologies of Advanced Therapies (LTTA), University of Ferrara, Ferrara, Italy.
Paolo
P
Pinton
Université Paris Descartes, Sorbonne Paris, Paris, France; the Metabolomics and Cell Biology Platforms, Institut Gustave-Roussy, Villejuif, France; INSERM, Centre de Recherche des Cordeliers, Paris, France; and Pôle de Biologie, Hôpital Européen Georges Pompidou, Paris, France.
Guido
G
Kroemer
D000818:Animals; D001343:Autophagy; D006801:Humans; D007659:Ketones / Q000737:chemistry*; D008928:Mitochondria / Q000502:physiology*; D057105:Nuclear Receptor Subfamily 4, Group A, Member 1 / Q000378:metabolism*; D011748:Pyrogallol / Q000031:analogs & derivatives* / Q000737:chemistry; D015398:Signal Transduction
C587356:1-(3,4,5-trihydroxyphenyl)nonan-1-one; D007659:Ketones; D057105:Nuclear Receptor Subfamily 4, Group A, Member 1; D011748:Pyrogallol